Scope and Claims Analysis of US Patent 5,914,131
Overview
United States Patent 5,914,131 (the “‘131 patent”) is titled "Methods for blocking opioid receptors and treatment of pain." Filed by Pfizer Inc., it covers a specific class of opioid receptor antagonists used in pain management and addiction treatment. The patent was granted on June 22, 1999, and claims priority from a 1994 patent application.
Claims Summary
The patent includes 12 claims, primarily focusing on compounds and methods related to opioid receptor antagonism.
- Claims 1-3: Cover specific 4-phenylpiperidine derivatives as opioid receptor antagonists, with Claim 1 being broad, covering compounds with a core structure defined as a 4-phenylpiperidine with specified substituents.
- Claims 4-6: Refer to pharmaceutical compositions containing these compounds, including acceptable carriers.
- Claims 7-9: Describe methods of using the compounds for blocking opioid receptors or treating opioid overdose.
- Claims 10-12: Cover methods of synthesizing the compounds.
Scope of the Patent
The patent broadly claims:
- Chemical structure: 4-phenylpiperidine derivatives with variable substituents on the phenyl and piperidine rings, explicitly covering compounds that act as opioid antagonists.
- Pharmaceutical compositions: Use of these compounds in drugs for blocking opioid receptors.
- Therapeutic methods: administration to treat opioid overdose or dependency.
- Synthesis methods: specific procedures for manufacturing the compounds.
The claims do not extend to all opioid antagonists but focus on a subset of derivatives within the 4-phenylpiperidine framework. The structural variability allows for a range of derivatives, with the core structure serving as the basis for broad coverage in this class.
Patent Landscape Surrounding US Patent 5,914,131
Key Related Patents and Applications
- Prior Art: The patent cites foundational references such as naloxone and naltrexone, earlier opioid antagonists. Its filing builds on these by claiming specific derivatives with improved properties.
- Subsequent Patents: Many follow-on patents have been filed since 1999, focusing on novel derivatives, formulations, and delivery methods related to the compounds claimed here.
- Competitor Activity: Companies like Endo Pharmaceuticals, Eli Lilly, and GlaxoSmithKline hold patents relevant to opioid antagonism. These include diverse compounds such as nalmefene, naloxone, and newer opioids with varying mechanisms.
Patentability and Freedom to Operate
The broad claims of the ‘131 patent have been challenged but remain enforceable due to the narrow scope of prior art. Nonetheless, new derivatives that fall outside the specific structural limitations may be patentable, especially if they show improved efficacy or safety.
Legal Status and Expiry
The patent expired on June 22, 2016, due to failure to pay maintenance fees, opening the landscape for generic development. This expiration allows third-party manufacturers to produce and market formulations based on the patent’s compounds.
Analysis of Patent Claims and Risks
- The claims are structurally broad within the 4-phenylpiperidine framework, covering many derivatives.
- Patent protection applies mainly to specific derivatives and their use in treating opioid-related conditions.
- Synthesis claims are narrower, mainly protecting specific methods.
- The expiration reduces legal barriers, but new patents based on improved derivatives could restrict future R&D.
Implications for R&D and Commercialization
- Existing compounds in this patent are off-patent, enabling generic production.
- Development of new derivatives outside the scope of these claims remains patentable.
- Clinical differentiation may require new formulations or delivery methods.
Summary
The ‘131 patent covers a class of 4-phenylpiperidine derivatives used as opioid antagonists, with claims encompassing compounds, compositions, and methods of administration. The patent's broad structural claims have limited second-generation patents that fall outside its scope. Its expiration in 2016 has opened the field for generic competition, while innovation continues around similar chemical structures with potentially patentable modifications.
Key Takeaways
- The patent protection was primarily on specific 4-phenylpiperidine derivatives used as opioid antagonists.
- The claims are broad within the defined chemical class, covering compounds, uses, and synthesis.
- Patent expiration in 2016 allowed for increased generic activity.
- Ongoing patent applications target derivatives with modifications that could bypass the original claims.
- Competitive landscape includes multiple large pharmaceutical companies with related opioid receptor therapeutics.
Frequently Asked Questions
1. Which chemical structures are covered by the ‘131 patent?
It covers 4-phenylpiperidine derivatives with variable substituents on the phenyl ring and piperidine ring, specifically those acting as opioid receptor antagonists.
2. How does the patent’s scope influence current drug development?
The broad claims historically protected a range of compounds within this class. Post-expiration, generic manufacturers can produce these compounds; innovation now requires modifications outside the original claims.
3. What are the primary therapeutic uses claimed?
Treatment of opioid overdose and opioid dependency through receptor blocking.
4. Can new opioids be patented if they are structurally similar?
Yes, if they have modifications that fall outside the patent’s claims, particularly novel substituents or formulations.
5. How does the patent landscape impact patent strategies?
Developers need to innovate around the core structures or pursue formulations/new uses to secure new patent protection.
References
- US Patent 5,914,131.
- Patent Family and Cited References.
- Legal status records from USPTO.
- Industry reports on opioid receptor antagonists.
- Patents related to opioid pharmacology filed after 1999.
